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Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder due to mutations in either TSC1 or TSC2 that affects
many organs with hamartomas and tumors. TSC-associated brain lesions include subependymal nodules, subependymal
giant cell astrocytomas and tubers. Neurologic manifestations in TSC comprise a high frequency of mental retardation and
developmental disorders including autism, as well as epilepsy. Here, we describe a new mouse model of TSC brain lesions in
which complete loss of Tsc1 is achieved in multiple brain cell types in a stochastic pattern. Injection of an adeno-associated
virus vector encoding Cre recombinase into the cerebral ventricles of mice homozygous for a Tsc1 conditional allele on the
day of birth led to reduced survival, and pathologic findings of enlarged neurons, cortical heterotopias, subependymal
nodules, and hydrocephalus. The severity of clinical and pathologic findings as well as survival was shown to be dependent
upon the dose and serotype of Cre virus injected. Although several other models of TSC brain disease exist, this model is
unique in that the pathology reflects a variety of TSC-associated lesions involving different numbers and types of cells. This
model provides a valuable and unique addition for therapeutic assessment.
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Introduction
Tuberous sclerosis complex (TSC) is a genetic disorder affecting
about 1 in 6,000 newborns caused by inactivating mutations in
Tsc1or Tsc2, encoding hamartin and tuberin, respectively [1,2].
Biallelic loss of either gene leads to chronic hyperactivation of
mTOR complex 1 (mTORC1), and this appears to be the primary
pathogenetic mechanism that leads to development of TSC
hamartomas in brain, kidney, skin, heart and lung [3,4]. Focal
brain pathologies, including cortical tubers and subependymal
nodules (SENs), are seen in the majority (.90%) of TSC patients,
and have been detected as early as late fetal gestation [5]. TSC
tubers disrupt neuronal laminar architecture, and tuber size and
number correlate with the incidence of infantile spasms and
epileptic seizures [6], as well as global developmental delay [7].
Most TSC patients develop multiple neurological manifestations
including seizures, intellectual deficit, neurobehavioral syndromes
including autism and autism spectrum disorder, and sleep
disorders [3]. Five to 10% of SENs show progressive enlargement,
are then called subependymal giant cell astrocytomas (SEGAs),
and can lead to devastating neurologic consequences due to
blockage of cerebrospinal fluid (CSF) flow and progressive
hydrocephalus.
Although there is clear evidence that loss of a single allele of
Tsc1or Tsc2 can affect global brain function [8,9], both tuber giant
cells and SEGA cells show evidence of complete loss of the TSC1/
TSC2 complex with constitutive activation of mTORC1,
augmented protein translation [10], reduced autophagy [11,12],
and endoplasmic reticulum (ER) and oxidative stress [13]. In
addition, cortical tubers contain much higher levels of inflamma-
tory cytokines than normal brain [14], suggesting an inflammatory
contribution to TSC brain pathogenesis in humans.
A number of mouse models of TSC brain disease have been
generated using conditional alleles of either Tsc1 or Tsc2, and a
variety of Cre recombinase alleles driven by different brain-specific
promoters, typically active during embryonic development, and in
some cases drug-inducible. Promoters have included those
selective for neuroprogenitor cells, neurons and astrocytes (e.g.
[9,15–23]). In general widespread recombination in brain cells is
seen in these models, inducing several features of TSC, such as
epileptic seizures, prenatal onset of giant cell development,
abnormal brain development (including heterotopias), decreased
myelination, and hydrocephalus and premature death. In these
conditional models, hamartin or tuberin loss occurs in essentially
all of a specific subtype of brain cells at a particular time in
development, in contrast to human patients where it occurs in a
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selective loss of Tsc1 was achieved by in utero electroporation of a
Cre recombinase expression cassette under a strong constitutive
promoter into one hemisphere of embryonic conditional mice,
which led to localized white matter heterotopic nodules and tuber-
like lesions [24].Given the severity of neurological and cognitive
deficits in TSC, efforts continue to try to develop mouse models
which recapitulate TSC brain lesions as closely as possible in order
to understand the pathophysiology and explore treatment
paradigms.
In this study we aimed to recreate the stochastic nature of Tsc1
loss of function in human brains with respect to subsets of different
cell types being affected in order to model TSC brain pathology
and its effects. Loss of Tsc1 was induced by intracerebral
ventricular (ICV) neonatal injection of adeno-associated virus
(AAV) vectors encoding Cre recombinase, or green fluorescent
protein (GFP) as a control, under a strong constitutive promoter.
Two serotypes of AAV - AAVrh8 and AAV1 were used (the latter
at two titers), each expressing Cre driven by a strong constitutive
promoter, which has been shown to transduce a variety of cell
types throughout the mouse brain following ICV injections at birth
(P0) [25]. AAV-Cre vectors were injected ICV into Tsc1
c/cROSA
pups at P0. AAV-Cre injected mice died prematurely with varying
degrees of lacZ+ staining and brain pathology, including enlarged
brains with an abnormally smooth surface and hydrocephalus.
Immunocytochemical staining revealed scattered enlarged neu-
rons in the cortex and small cortical clusters of cells with dual
differentiation shown by immunostaining for both neuronal and
glial markers, as well as high phospho-S6 (pS6, Ser235/236)
expression in astrocytes and other cells indicative of Tsc1 loss and
mTORC1 hyperactivation. Thickening of the subependymal layer
of the ventricles was also noted, in some cases with small nodules
in the adjacent intraventricular cerebrospinal fluid (CSF). These
nodules stained positively for lacZ, doublecortin (DCX), glial
fibrillary acidic protein (GFAP) and the transmembrane glyco-
protein (GPNMB), similar to SENs seen in TSC patients.
Methods
AAV Vector Design and Packaging
AAV vector plasmid, AAV-CBA-Cre-BGHpA was derived
from the plasmid AAV-CBA-EGFP-W [25] by replacing EGFP
and WPRE element with the Cre recombinase cDNA. The AAV-
CBA-EGFP-W vector was used as a control. These AAV vectors
carry AAV2 ITR elements and gene expression is controlled by a
hybrid promoter (CBA) composed of the cytomegalovirus (CMV)
immediate/early gene enhancer fused to the chicken beta-actin
promoter. The identity of all PCR amplified sequences was
confirmed by sequencing.
AAVrh8 and AAV1 serotype vectors were produced by
transient co-transfection of 293T cells by calcium phosphate
precipitation of vector plasmids (AAV-CBA-Cre or AAV-CBA-
GFP-W), adenoviral helper plasmid pFD6 and a plasmid encoding
for the AAVrh8 cap (pAR-rh8) or AAV1 cap gene (pXR1), as
previously described [25]. Briefly, AAV vectors were purified by
iodixanol gradient centrifugation followed by column chromatog-
raphy using HiTrapQ anion exchange columns (GE Healthcare,
Piscataway, NJ, USA). The virus-containing fractions were
concentrated using Centricon 100 kDa MWCO centrifugal
devices (EMD Millipore, Billerica, MA, USA) and the titer
[genome copies (g.c.)/ml] was determined by real-time PCR
amplification with primers and probe specific for the bovine
growth hormone polyadenylation signal.
Animals and ICV Injections
Experimental research protocols were approved by the Institu-
tional Animal Care and Use Committee (IACUC) for the
Massachusetts General Hospital (MGH) following the guidelines
of the National Institutes of Health for the Care and Use of
Laboratory Animals. Experiments were performed on Tsc1
c/c mice
which also carried the Cre-inducible ROSA26 lacZ marker allele,
as described [26,27]. In response to Cre recombinase the Tsc1
c/c
allele is converted to a null allele, and the lacZ allele expresses b-
galactosidase. These mice have a normal lifespan.
For vector injections, on the day of birth (P0), neonates were
cryo-anesthetized and injected with 2 ml of viral vector into each
cerebral lateral ventricle with a glass micropipette (70–100 mm
diameter at the tip) using a Narishige IM300 microinjector at a
rate of 2.4 psi/sec (Narshige International, East Meadow, NY,
USA). The viral vector solution consisted of either 2610
10 g.c. per
2 mlo r2 610
9 g.c. per 2 ml. Mice were then placed on a warming
pad and returned to their mothers after regaining normal color
and full activity typical of newborn mice. Mice were euthanized
when they showed a weight loss of .15%, greatly reduced
movement or other signs of distress.
X-gal Staining
Mice were sacrificed using CO2 generated from dry ice and
brains were rapidly frozen in 2-methyl-butane/dry ice bath.
Coronal serial sections were cut to a thickness of 10 mm using a
cryostat, directly mounted on glass slides and stored at 280uC.
Slides were fixed in 0.25% glutaraldehyde in PBS (pH 7.4) for
20 min, stained in X-gal solution (Gold Biotechnology, St. Louis,
MO, USA) overnight at 37uC and counterstained with Nuclear
Fast Red solution (Vector Laboratories, Burlingame, CA, USA).
Histology and Immunohistochemistry (IHC)
For standard histologymouse brains were prepared after
euthanasia with CO2by immediate removal of brains and 2–4
days of fixation in Bouin’s solution (VWR International, Radnor,
PA). Following paraffin embedding, 5 mm sections were cut and
Figure 1. Survival of Tsc1
c/c mice injected ICV with AAVrh8-
CBA-GFP or AAVrh8-CBA-GFP at P0. Survival is shown for Tsc1
c/c
pups injected with the AAV-Cre (N=15) or the AAV-GFP (N=13) vectors
as a control, both at 2610
10 g.c. per 2 ml into each ventricle. Median
survival of the Cre injected mice was 38 days; controls survived .90
days. Difference between groups p,0.0001.
doi:10.1371/journal.pone.0064224.g001
Stochastic Model of Tsc1 Lesions in Mouse Brain
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e64224stained with either Haematoxylin and Eosin (H&E) or were used
for IHC. IHC was performed after deparaffinization and re-
hydration steps and antigen retrieval in citrate buffer (pH 6) using
the EnVision System (Dako, Carpinteria, CA, USA) or Histo-
Mouse-Plus kit (Invitrogen, Carlsbad, CA, USA), per manufac-
turer’s instruction. pS6 antibody (#2211) and TSC2 antibody
(#4308) were from Cell Signaling (Danvers, MA, USA).
For DCX, GFAP, NeuN and GPNMB staining, sections were
deparaffinized in xylenes followed by re-hydration in decreasing
ethanol concentrations. Endogenous peroxidase was blocked with
0.5% hydrogen peroxide, then tissues were washed in PBS. Heat-
induced antigen retrieval was performed using sodium citrate
10 mM, pH 6.0, in a 95uC water bath (20 min for GPNMB and
30 min for DCX). Tissues were blocked in a 10% normal goat
serum (GPNMB) or 10% normal horse serum (GFAP, DCX,
NeuN) then incubated overnight with primary antibody. Dilutions
were: 1:300 rabbit polyclonal GPNMB (Lifespan Biosciences,
Seattle, WA, USA) LS-C80662/28556, 1:250 goat polyclonal
DCX (Santa Cruz Biotechnologies, Santa Cruz, CA, USA, sc-
8066), 1:400 mouse monoclonal NeuN (MAB377, EMD Millipore)
and 1:800 mouse monoclonal GFAP (Sigma, St. Louis, MO, USA,
C9205). Tissues were incubated for 30 min with secondary
antibody 1:250 biotinylated goat anti-rabbit (Vector Laboratories,
BA-1000), 1:250 biotinylated horse anti-goat (Vector Laboratories,
BA-9500) and 1:250 and 1:400 biotinylated horse anti-mouse
(Vector Laboratories, BA-2000), washed in PBS and incubated
with avidin-biotin complex (Vector Laboratories, PK-6100) for
30 min. Staining was performed with 3,39-diaminobenzidine
(DAB) in H2O2 (Vector Laboratories), then counterstained with
haematoxylin, dehydrated and coverslipped.
Immunostaining with NeuN, GFAP and pS6; Neuronal
Cell Measurements
Mice were sacrificed at 1 month of age by transcardiac
perfusion with PBS followed by ice-cold 4% paraformaldehyde
in PBS. Brains were dissected and post-fixed for 4 hrs at 4uC,
followed by overnight incubation in 30% sucrose in PBS at 4uC
and were embedded in tissue freezing medium (Tissue-Tek O.C.T
compound, Sakura Finetek Inc., Torrance, CA, USA). Coronal
serial sections were cut to a thickness of 10 mm and directly
mounted on glass slides. Sections were stained for the neuronal
marker, 1:1000 mouse monoclonal NeuN (MAB377, EMD
Millipore) or glial marker, 1:500 mouse monoclonal anti-GFAP
(Clone G-A-5 Cy3 conjugate, Sigma), or for pS6 - 1:1000 pS6
rabbit antibody (Cell Signaling) in 0.1% Tween-20 in PBS
overnight at 4uC, washed in PBS 3610 min, incubated for
30 min with 1:1000 Alexa 488-conjugated goat anti-mouse
secondary antibody (Life Technologies, Grand Island, NY, USA)
or 1:1000 Alexa 546-conjugated anti-rabbit secondary antibody
(Life Technologies) in 0.1% Tween-20 in PBS. After another
3610 min washes in PBS, sections were counterstained with 4,6
Figure 2. Cre-mediated recombination in Tsc1
c/c mice after injection of AAVrh8-CBA-Cre at birth. In Tsc1
c/c mice, Cre-mediated
recombination knocks-out the floxed Tsc1 allele and knocks-on a transgenic lacZgene. These mice were injected at P0 with AAV8-CBA-Cre vector
(2610
10g.c. in each ventricle), and lacZ expression throughout the brain was analyzed at ,P28 as a marker of recombination efficiency. (A) AAV-
treated Tsc1
c/cROSA mice displayed intense lacZ expression throughout the brain, (B) while uninjected controls were devoid of any lacZ activity. Ten
mm sections were stained with X-gal solution and counterstained with Nuclear Fast Red. Scale bars: 1 mm. (C & D) Staining for NeuN shows that
neurons above the lateral ventricles in AAVrh8-CBA-Cre injected mice were considerably larger than in control uninjected mice Scale bars: 200 mm. (E)
The periventricular neurons of the brains of AAV-Cre injected and non-injected mice (P28) were immunostained for the neuronal marker, NeuN and
the widest diameter of stained cell bodies was measured in .180 randomly selected cells from several fields with 3 animals per group. The AAV-Cre
injected cortical neurons had an almost 2-fold increase in diameter, shown as mean6SEM (*p,0.001).
doi:10.1371/journal.pone.0064224.g002
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PBS and coverslipped.
In NeuN immunofluorescence stained brains, the widest
diameter of NeuN+ cells in cortex was measured using Metavue
software (Molecular Devices, Sunnyvale, CA, USA) for 180
randomly selected cells in the cortex just above the lateral
ventricles from 3 animals in each group. In NeuN immunostained
brain, the widest diameter of NeuN+ cells in cortex was measured
using photoshop software (Adobe) for 30 randomly selected cells in
the cortex just above the lateral ventricles from 3 animals in each
group.
MRI
The mice were scanned using a T2-weighted TurboRARE-3D
(TE=43 ms and TR=1200 ms) sequence for a 19262566192
matrix and a voxel size of 0.097660.13061.302 mm after
reconstruction on a Bruker Pharmascan 4.7 tesla magnet using a
Bruker mouse brain coil (Model T8118, Bruker Scientific
Instruments, Billerica, MA USA). Regions of interest (ROI) of
the brains were automatically segmented using a house-built
Matlab program by searching for the largest connected region of a
given threshold. These ROI’s were manually modified using
Amira software (Amira, Burlington, MA, USA) to check for any
anomalies in the auto-segment routine. An additional ROI was
manually drawn to represent the normal brain tissue and, utilizing
a region-based threshold that 3 standard deviations above the
mean normal brain value, the CSF was segmented. This
segmented region was manually modified by removing any
spurious voxels above this threshold around the edges of the
brain that were due to partial volume effect.
Statistical Analysis
All analyses of survival curves (Chi square test) and brain
ventricular volumes (t test) were performed using GraphPad Prism
software (GraphPad Software, Inc., La Jolla, CA, USA). The p
values depicted are statistically significant.
Results
AAVrh8-CBA-Cre Injections into Tsc1
c/c Mice
We initially evaluated the survival of Tsc1
c/c mice receiving an
ICV injection of AAVrh8-CBA-Crevectorat P0 (2610
10 g.c. per
2 ml into each ventricle). In contrast to mice receiving a control
injection of an AAVrh8-CBA-GFP vector, AAVrh8-CBA-Cre
injected mice showed a median survival of 38 days (Fig. 1,
p,0.0001). GFP immunostaining of brains of AAVrh8-CBA-GFP
injected mice and non-injected mice at 110 days showed GFP
positive cells of different morphologies throughout the periven-
Figure 3. LacZ and GFAP expression in AAVrh8-CBACre injected Tsc1
c/cROSA mice. Tsc1
c/cROSA mice were injected at P0 with AAVrh8-CBA-
Cre vector (2610
9g.c. in each ventricle), and lacZ expression in the brain was analyzed at 6 months (N=2). (A & B) LacZ+ cells were observed scattered
as single cells or in patches throughout the cortex. (C & D) Immunocytochemical staining for GFAP with DAPI dye staining of nuclei revealed
numerous foci of GFAP+ (red) cells in the cortex (C) while uninjected controls were devoid of any GFAP+ cells in the cortex (D). Scale bars: A–D:
200 mm.
doi:10.1371/journal.pone.0064224.g003
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latter (Fig. S1).
Brains obtained from Tsc1
c/c mice injected with the AAVrh8-
CBA-Cre vector collected at P30 (N=3) appeared enlarged and
swollen. Staining with lacZ typically showed widespread evidence
of recombination (Fig. 2A), while brains from non-injected Tsc1
c/c
mouse controls at the same age showed no lacZ staining (Fig. 2B).
NeuN staining (Fig. 2C and D) demonstrated that neurons near
the periventricular area chosen from each brain had an average
diameter of 16.960.22 mm in AAVrh8-CBA-Cre injected mice in
comparison to 9.260.21 mm for non-injected animals (Fig. 2E),
representing an almost 2-fold increase in neuronal diameter in the
Tsc1 knock-out brains (p,0.001).
Since the above mice demonstrated high level and global brain
recombination, we also injected two Tsc1
c/c mice with a lower dose
of AAVrh8-CBA-Cre 2610
9 g.c. per 2 ml into each ventricle (1/
10
th that of above animals). These two mice survived for 180 days
when they developed mild signs of distress characterized by a
hunched back. Neuropathologic examination of their brains
showed fewer lacZ+ cells, occurring in a scattered pattern and in
clusters throughout the cortex (Fig. 3A and B). Staining for an
astrocytic marker (GFAP) in these mice revealed clusters of
positive cells in the AAVrh8-CBA-Cre-injected Tsc1
c/c mice
(Fig. 3C), which were absent in un-injected Tsc1
c/c mouse brain
(Fig. 3D). Some of the cells in GFAP+ clusters in AAVrh8-CBA-
Cre-injected Tsc1
c/cROSA pups also stained for NeuN suggesting
a possible mixed cell lineage phenotype (Fig. 4A), although the
small size of the apparently co-staining cells was unexpected.
Further, enlarged neurons in AAVrh8-CBA-Cre-injected Tsc1
c/c
mice showed strong staining for pS6 (Fig. 4B).
To achieve a milder phenotype than in the Tsc1
c/c mice injected
with high titer AAVrh8-CBA-Cre, we also tested an AAV1-CBA-
Cre vector since AAV1 vectors have been shown to transduce
fewer brain cells in mouse pups after neonatal ICV injection [25].
ICV injection of AAV1-CBA-Cre vector (2610
10 g.c. per 2 ml into
each ventricle) in P0 Tsc1
c/c pups produced a somewhat longer
median survival time (median of 66.5 days, range 30–150 days),
while parallel injection of an AAV1-CBA-GFP vector did not
result in any animal death over 200 days (Fig. 5,p ,0.0001). To
confirm that recombination had occurred at the Tsc1 locus in the
brains of mice subject to injection of the AAV1-CBA-Cre, we
performed multiplex ligation-dependent probe assay (MLPA).
MLPA can be used to determine the extent of recombination of
the c to the k (null) allele at Tsc1 in a quantitative fashion, as
described [28,29]. Ten % recombination was found in the brains
Figure 4. GFAP, NeuN and pS6 staining in brains of AAVrh8-CBA-Cre injected and non-injected Tsc1
c/cROSA mice at 1 month. (A) Co-
immunostaining for GFAP and NeuN in AAVrh8-CBA-Cre injected Tsc1
c/cROSA mice showed clusters of GFAP+ cells in the cortex, some of which co-
stained for NeuN (arrows). Scale bars: a–c-:200 mm; d–f: 50 mm. (B) Co-immunostaining for pS6 and NeuN in AAVrh8-CBA-Cre injected Tsc1
c/cROSA
mice and non-injected mice (a–c) Cells were larger in AAVrh8-CBA-Cre injected mice than in controls and stained more strongly for pS6. Scale bars: a–
f: 200 mm.
doi:10.1371/journal.pone.0064224.g004
Figure 5. Survival data (Kaplan-Meier curve) of Tsc1
c/cROSA
mice injected ICV with AAV1-CBA-GFP or AAV1-CBA-Cre at P0.
Death was determined by the point at which animals were in severe
distress at which time they were euthanized. Tsc1
c/cROSApups (N=20)
injected with the AAV-CBA-Cre vector died over a range of 30–150 day
postnatal period, with a mean of 66.5 survival days. The same P0 pups
injected ICV with AAV-GFP as a control (dashed line) all survived .200
days, the longest time point analyzed (N=8). p,0.0001.
doi:10.1371/journal.pone.0064224.g005
Stochastic Model of Tsc1 Lesions in Mouse Brain
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injected animals (Fig. S2).
Extensive histological analysis was carried out on Tsc1
c/c mice
following P0 ICV injection of AAV1-CBA-Cre or AAV1-CBA-
GFP sacrificed at different time points. Severe hydrocephalus was
seen in 2 of 10 AAV1-CBA-Cre injected brains, and mild
hydrocephalus in 6 of 10 brains in animals sacrificed at 1–5
months of age due to signs of distress, including hunched back,
dehydration and weight loss. In contrast, mild hydrocephalus was
seen in only 1in 6 brains of animals injected with the AAV1-CBA-
GFP control vector (p,0.0041; Table S1) and none of the control
animals showed signs of distress, nor did any of the AAV1-CBA-
GFP injected controls in the survival curves out to 200 days
(Fig. 5).
Brains obtained from Tsc1
c/c neonatal mice injected with the
AAV1-CBA-Cre vector collected at P30 (N=3) appeared
enlarged, as compared with parallel mice injected with the
AAV1-CBA-GFP vector or non-injected (N=3, respectively; data
not shown). NeuN staining in AAV1-CBA-Cre injected brains
(Fig. 6A) demonstrated that neurons near the periventricular
region had an average diameter of 32.766.0 mm, in comparison
to 17.062.4 mm for AAV1-CBA-GFP injected mice (Fig. 6B) and
18.462.6 mm for non-injected animals (Fig. 6C), representing an
almost 2-fold increase in neuronal diameter in the Tsc1 knock-out
brains (Fig. 6D;p ,0.0001).
To assess astrocyte transduction, brains of AAV1-CBA-Cre and
AAV1-CBA-GFP neonatal injected Tsc1
c/c mouse brains at P30
were co-stained with pS6 and GFAP antibodies and counter-
stained with haematoxylin. In the AAV1-CBA-Cre injected
brains, intermediate or mixed cells stained for both the markers
in the periventricular regions (Fig. 7A) and subependymal lining
(Fig. 7B), which corresponds to the location of SEGAs in Tsc
patients. Co-localization in the cortex was seen only in very few
cells (Fig. 7C). No co-staining was seen in the AAV1-CBA-GFP
injected brains (Fig. 7D). Pairs of AAV1-CBA-Cre and AAV1-
CBA-GFP injected Tsc1
c/c mouse brains were examined at P30,
demonstrating that brains of AAV1-CBA-Cre-injected mice were
enlarged and had a smoother surface, as compared to control
vector injected brains, although the weight of the brains was not
significantly different between the two groups (data not shown).
Four mice injected ICV at P0 with AAV1-CBA-Cre and 2 mice
injected in parallel with AAV1-CBA-GFP were examined by
Figure 6. NeuN staining for neuronal diameter measurements. Immunostaining for NeuN (counterstained with haematoxylin) shows that
neurons above the lateral ventricles in (A) AAV1-CBA-Cre injected Tsc1
c/c mice were considerably larger than those in controls in the same region: (B)
AAV1-CBA-GFP injected and (C) uninjected mice. Magnification=40X. (D) Periventricular neurons in the brains of AAV1-Cre and AAV1-GFP injected, as
well as non-injected mice (P30) were stained for the neuronal marker, NeuN and the widest diameter of stained cell bodies was measured in .30
randomly selected cells from several fields with 3 animals per group. Neurons in the AAV1-CBA-Cre injected brains had an almost 2-fold increase in
diameter, as compared to controls, shown as mean6SEM (*p,0.0001).
doi:10.1371/journal.pone.0064224.g006
Stochastic Model of Tsc1 Lesions in Mouse Brain
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with volumetric analysis of brain regions. Ventricular volume was
about 4 times larger in the AAV1-CBA-Cre injected vs. control
injected mice (Fig. 8A,p ,0.044), while the brain tissue volume
was only about 6% larger on average in the former (Fig. 8B,p
value non-significant). In addition to enlarged ventricles, in three
of the four AAV1-CBA-Cre injected mice, nodules and thickening
of the ventricular lining were noted (arrowheads in Fig. 9A and
B), while no abnormalities were seen in control vector injected
mice (Fig. 9C). In one AAV1-CBA-Cre injected mouse brain
there was an apparent increased geographic signal abnormalities
in the brain, which may represent cortical tubers or dysplasia, not
seen in controls (Fig. S3).
LacZ staining of the brains of the AAV1-CBA-Cre injected
Tsc1
c/c mice sacrificed at 1 month revealed clusters of positive cells
scattered throughout the brain and strong staining around the
ventricles (Fig. 10A; Note, also the enlarged lateral ventricles.)
Higher magnification of the ventricular regions showed thickening
of the ventricular layer associated with lacZ+ cells indicative of
recombination and Tsc1 loss (Fig. 10B), as well as clusters of lacZ+
cells near the ventricles and a lacZ+ nodule protruding into the
ventricle (Fig. 10C), and a nodule of undifferentiated cells
budding off the subependymal surface with clear staining of cell
nuclei with haematoxylin (Fig. 10D).
Coronal sections of brains of AAV1-CBA-GFP and AAV1-
CBA-Cre injected Tsc1
c/c mice sacrificed at P30 showed massively
enlarged lateral ventricles for the latter (Fig. 11A, top), which
appeared to result from a constriction between the 3rd and lateral
ventricles, as the 3rd ventricle, 4th ventricle and aqueduct
appeared to be of normal size. Immunohistochemical staining
for pS6 revealed strong signal in enlarged cells in the cortex of
AAV1-CBA-Cre injected animals, as compared to AAV1-CBA-
GFP injected animals (Fig. 11A, bottom). Enlarged pS6+ cells, as
compared to controls, were seen throughout most regions of the
Figure 7. pS6 and GFAP double immunostaining to assess astrocyte transduction. Tsc1
c/cROSA homozygous pups were injected ICV at P0
with either an AAV1-CBA-GFP or AAV1-CBA-Cre vector at a concentration of 2610
10g.c. One month later two of the pups injected with AAV1-CBA-Cre
virus who developed distress were sacrificed and showed severe hydrocephalus by neuropathological examination. To assess astrocyte transduction,
the brains were double stained for pS6 and GFAP and counter stained with haematoxylin. Intermediate or mixed cells which stain for both the
markers were seen in the (A) periventricular region and (B) subependymal lining. No co-localization was seen in the cortex except for a very few
cells(C). No double staining was seen in any region of the brain in AAV1-GFP injected brain (D). Arrows indicate double stained cells.
Magnification=40X.
doi:10.1371/journal.pone.0064224.g007
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c/c pups at 1 month of age after P0 ICV injection. Injection of AAV1-
CBA-Cre (N=4) or AAV1-CBA-GFP (N=2) 2610
10 g.c. per 2 ml into each ventricle was carried out on P0 and MR images were evaluated on P30. (A)
Measurement of ventricle size in voxels (each voxel=0.097660.13061.302 mm).Difference between groups is significant (p,0.044). (B) Measurement
of brain parenchyma (excluding ventricle volume) in voxels. Difference between groups, p,0.23, not significant. Measurements were made by
observer blinded to genotype.
doi:10.1371/journal.pone.0064224.g008
Figure 9. Representative MR images of AAV1-CBA-Cre and AAV1-CBA-GFP injected mouse brains. AAV1-CBA-Cre injected mouse brains
(see Fig. 8 legend) showed abnormalities associated with the ventricular regions. (A) Multiple apparent subependymal nodules (arrowheads) were
seen in the ventricles in the brains of two AAV1-CBA-Cre injected mice. First two images are from the same mouse. (B) Ventricles also appeared to
have thickening of the ependymal lining (arrowheads; two left panels). (C) None of these abnormalities were observed in the control vector (AAV1-
CBA-GFP)-injected brains.
doi:10.1371/journal.pone.0064224.g009
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hippocampus, cerebellum, and caudate, with less difference
compared to controls seen in the brainstem (Fig. 11B).
In order to identify the phenotype of the abnormal ventricular
structures in AAV1-CBA-Cre injected Tsc1
c/c mice, as compared
to AAV1-CBA-GFP injected animals, additional immunohisto-
chemical staining was performed. Staining for doublecortin (DCX;
a marker for migratory neuroblasts in the subventricular zone [30]
revealed positive regions along the ventricles in control animals,
but those regions were enlarged in AAV1-CBA-Cre injected
animals (Fig. 12A, upper panels). In addition, the latter animals
showed small DCX positive nodules attached to the ventricular
wall or sometimes appearing to be floating in the CSF (Fig. 12A,
lower panels), which were not seen in control animals. No strong
GFAP staining was seen in the ventricular lining of control brains,
but was intense in some subventricular regions of the AAV-CBA-
Cre injected Tsc1
c/c mice, including some GFAP positive nodules
in the CSF space (Fig. 12B). We also noted strong staining for
GPNMB (transmembrane glycoprotein found in human subepen-
dymal nodules) [31] in AAV1-CBA-Cre injected brains, but not in
AAV1-CBA-GFP injected brains (Fig. 12C). In one AAV1-CBA-
Cre injected animal immunostaining with NeuN highlighted a
superficial cortical nodule formed by a focal herniation of cortical
layers I and III through the molecular layer and neurons of various
sizes grouped around a central blood vessel (Fig. 12D). Cortical
nodules with a similar histological appearance in humans are
known as nodular cortical dysplasia or ‘‘brain warts’’. No other
cortical lesions were observed at the neuropathological level in the
four AAV1-CBA-Cre injected mice analyzed by MRI.
Discussion
In this study we have generated a new model of TSC brain
disease by exogenous injection of Cre expressing AAV virus at
birth to pups that are homozygous for the conditional allele of
Tsc1, Tsc1
c/c mice. To our knowledge this method of induction of
Tsc1 or Tsc2 loss in the developing brain has not been reported
Figure 10. Cre-mediated recombination in Tsc1
c/c mice after neonatal delivery of AAV1-CBA-Cre vector (2610
10 g.c. per 2 ml into
each ventricle). (A) Three months after ICV vector injection into Tsc1
c/cROSA homozygous pups, frozen sections were stained with X-gal and
counterstained with Nuclear Fast Red. Intense lacZ staining was visualized in clusters throughout the brain(coronal section, anterior to hippocampus
region); note enlarged ventricles (V). Magnification=2X. (B) The ventricular lining showed patches of lacZ staining and thickening. (C) Nodule-like
structure, composed of cells in which Cre recombination has been induced as visualized by X-gal staining, were observed in the ventricles. (D) H&E
staining showing nodule along ventricular lining. The regions in B, C & D are taken at a level close to the anterior amygdala. Magnification B, C &
D=10X.
doi:10.1371/journal.pone.0064224.g010
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been described (for references, see Introduction), this new model
has several features that are of interest. First, the brains of treated
mice contain large numbers of pS6+ neurons reflecting effects of
loss of Tsc1 and development of cells that approach giant cells in
their morphology. Second, at lower vector doses, we achieved
variable, mosaic loss of Tsc1 both in scattered cells and in focal
regions, similar to cortical tubers. Third and arguably most
interesting was the development of consistent hypertrophy of the
subependymal layer, with expansion of the normal 1 cell thick
layer into a convoluted layer with projections and apparently
isolated nodules in the CSF. This subependymal proliferation
appeared to be the cause of hydrocephalus in these mice, which
was a major contributor to their morbidity and mortality.
Subependymal nodules (SENs) are seen in the great majority of
TSC children. The potential for growth of these lesions has led to
formal guidelines that recommend frequent periodic screening by
MRI in TSC children and young adults. Further, a recent report
indicated that about one third of SENs were observed to grow over
a 4-year period postnatally [32]. Moreover, progressive increase in
size of a SEN to a diameter .1 cm is seen in 5–10% of all children
with TSC, necessitating intervention by either treatment with
mTOR inhibitors, rapamycin [33] or everolimus [34,35], or
surgical removal [36,37]. The consistent development of similar
subependymal proliferative lesions in this new mouse model
enables investigation of therapeutic strategies, including other
mTOR inhibitors and novel approaches. The ability to titrate the
dose of virus injected and thereby the severity of disease induced
makes this model particularly useful in this regard.
Although rapamycin and related drugs represent a major
breakthrough in the therapy of TSC tumors that develop at
multiple sites [38,39], there is continuing need for improvement in
therapies, particularly those that address the diverse array of
neurologic and neurobehavioral consequences of TSC brain
involvement. Our current studies provide proof of concept that
AAV vector delivery to the neonatal mouse brain can be exploited
Figure 11. Hydrocephalus and enlarged pS6+ cortical cells in Tsc1
c/c mice injected with AAV1-CBA-Cre vector. Tsc1
c/cROSA
homozygous pups were injected ICV at P0 with either an AAV1-CBA-GFP (N=6) or AAV1-CBA-Cre (N=10) vector at a concentration of 2610
10g.c per
ventricle. One month later pups which had received AAV1-CBA-Cre virus developed tremor (N=8) and were found to have hydrocephalus by
pathologic analysis (N=2). (A) Representative images of brain (upper panels) and cerebral cortex (lower panels) showing in AAV1-CBA-Cre injected
animals severe hydrocephalus, large portion of enlarged cortical cells with strong pS6-positivity, and condensed cortical thickness due to swelling of
ventricles. Scale bars=1 mm, upper; 100 mm, lower. (B) Representative pS6 staining in different brain regions. Enlarged pS6+ cells were ectopically
present in striatum oriens of hippocampus (arrowhead) due to migration defect of Tsc1-null cells. Some pS6+ Purkinje cells in the cerebellum as well
as neurons in the caudate were notably enlarged (arrowheads). Neural cells in deep nuclei such as the brain stem showed similar distribution of pS6
positivity in Cre and GFP injected mice. Scale bars=50 mm.
doi:10.1371/journal.pone.0064224.g011
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same approach to deliver Tsc1 or Tsc2 (rather than Cre
recombinase) by similar means to brain cells, and reverse the
complex set of neuropathology and phenotypes induced by loss of
these genes. Hence, these studies are the first step in the
exploration of possible gene therapy as a therapeutic strategy in
TSC.
Supporting Information
Figure S1 GFP staining on the AAVrh8-CBA-GFP inject-
ed brains. Brains of AAVrh8-CBA-GFP injected at P0 and
uninjected Tsc1
c/c mice at P30 at 110 days were stained for GFP
and counter stained with haematoxylin. Positive staining was
revealed throughout the brain, shown here in the cortex in the
cortex and the ventricles in the AAV injected mice. Magnifica-
tion=20X.
(TIF)
Figure S2 Evidence of recombination at the target Tsc1
gene. To confirm that recombination had occurred at the Tsc1
locus in the brains of mice subject to injection of the AAV-Cre, we
performed multiplex ligation-dependent probe assay (MLPA).
MLPA can be used to determine the extent of recombination of
the c to the k (null) allele at Tsc1 in a quantitative fashion, as
described (28,29). Capillary electrophoresis tracings are shown for
5 DNA samples. The peak on the left reflects the abundance of the
c allele; that on the right reflects the abundance of the k allele.
Samples A–E are: A) control Tsc1ck blood DNA sample; B)
control Tsc1
c/c mouse brain sample at age 1 month after AAV1-
CBA-GFP injection; C) control Tsc1
c/c mouse brain sample at age
3 months after AAV1-CBA-GFP injection; D) Tsc1
c/c mouse brain
sample at age 1 month after AAV1-CBA-Cre injection; E) control
Tsc1
c/c mouse brain sample at age 3 months after AAV1-CBA-Cre
injection. Note. The A (control) sample shows roughly equal
amounts of signal for the c and k alleles; samples B and C show no
k allele signal; and samples D and E show approximately 90% c
and 10% k signal.
(TIF)
Figure S3 MR images from AAV1-CBA-Cre and AAV1-
CBA-GFP injected mice. Coronal (top panels) and sagittal
(bottom panels) pseudocolored images are shown for AAV1-CBA-
Cre (left panels, two different animals) and AAV1-CBA-GFP (right
panels) injected animals. Apparent geographical areas of higher
signal abnormally in the cortical/subcortical zones were noted in
one AAV1-CBA-Cre injected animal and not in controls.
(TIF)
Table S1 Histological analysis was carried out on Tsc1
c/c mice
following P0 ICV injection of AAV1-CBA-Cre or AAV1-CBA-
GFP sacrificed at different time points. Severe hydrocephalus was
seen in 2 of 10 AAV1-CBA-Cre injected brains, and mild
hydrocephalus in 6 of 10 brains in animals sacrificed at 1–5
Figure 12. DCX, GFAP, GPNMB and NeuN staining in brains of AAV1-CBA-Cre and AAV1-CBA-GFP P0 injected Tsc1
c/c mice at 1
month. Tsc1
c/cROSA homozygous pups were injected ICV at P0 with either an AAV1-CBA-GFP or AAV1-CBA-Cre vector at a concentration of
2610
10g.c. One month later pups injected with AAV1-CBA-Cre virus were sacrificed and processed for immunohistochemistry and showed severe
hydrocephalus (N=2). The pups (A) Staining for DCX revealed positive regions along the ventricles(anterior to the striatum, at the level of septal
nuclei) in control animals (Fig. 12A, top left panel), but those regions were enlarged in AAV1-CBA-Cre injected animals (Fig. 12A, top right). In
addition, the latter animals showed small DCX positive nodules [Fig. 12A, bottom left (level close to anterior amygdale) and right (level of septal
nuclei)], which were not seen in control animals. (B) No strong GFAP staining were seen in the ventricular lining (level of septal nuclei) of control
brains, but was intense in some subventricular regions (anterior to striatum) of the AAV1-CBA-Cre injected animals (Fig. 12B, top panels), including
some GFAP positive nodules in the CSF space at the level of septal nuclei (Fig. 12B, bottom panel). (C) GPNMB staining was virtually null in control
brains, with some positive cells near the ventricles anterior to striatum in AAV1-CBA-Cre injected animals (Fig. 12C). (D) NeuN staining of brains
revealed rare heterotopias (arrow) consisting of outgrowth of glial cells into the cerebral cortex. Magnification=20X.
doi:10.1371/journal.pone.0064224.g012
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dehydration and weight loss. In contrast, mild hydrocephalus was
seen in only 1in 6 brains of animals injected with the AAV1-CBA-
GFP control vector.
(XLS)
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